Journal: Biomedicines

Article Title: A UHPLC–MS/MS Method for Therapeutic Drug Monitoring of Aciclovir and Ganciclovir in Plasma and Dried Plasma Spots

doi: 10.3390/biomedicines9101379

Figure Lengend Snippet: The mean calibration curves (9 point calibration curve) of ganciclovir and aciclovir ranging from 0.01 to 20 mg/L in plasma (panel a ) and in DPS (panel b ).

Article Snippet: Aciclovir (ref. A192400) and ganciclovir-d5 (ref. G235002) were purchased from Toronto Research Chemicals (North York, ON, Canada).

Techniques: Clinical Proteomics

Journal: Biomedicines

Article Title: A UHPLC–MS/MS Method for Therapeutic Drug Monitoring of Aciclovir and Ganciclovir in Plasma and Dried Plasma Spots

doi: 10.3390/biomedicines9101379

Figure Lengend Snippet: Chromatograms obtained: a calibrator at the LLOQ in plasma (panel 1.a , aciclovir; panel 2.a , ganciclovir); deuterated internal standards (panel 3.a , ganciclovir-d5) and a calibrator at the LLOQ in DPS (panel 1.b , aciclovir; panel 2.b , ganciclovir); deuterated internal standards (panel 3.b , ganciclovir-d5). RT, retention time; AA, automatic area; SN, signal-to-noise ratio; NL, normalized level.

Article Snippet: Aciclovir (ref. A192400) and ganciclovir-d5 (ref. G235002) were purchased from Toronto Research Chemicals (North York, ON, Canada).

Techniques: Clinical Proteomics

Journal: Biomedicines

Article Title: A UHPLC–MS/MS Method for Therapeutic Drug Monitoring of Aciclovir and Ganciclovir in Plasma and Dried Plasma Spots

doi: 10.3390/biomedicines9101379

Figure Lengend Snippet: Results of intra-day and inter-day accuracy and reproducibility assays for plasma and DPS ( n , replicates; ( n ) = 5). The quality control concentrations were, respectively, 0.01, 0.02, 0.5, and 10 mg/L for LLOQ, QClow, QC medium, and QC high. (SD, Standard deviation; CV%, coefficient of variation percentage).

Article Snippet: Aciclovir (ref. A192400) and ganciclovir-d5 (ref. G235002) were purchased from Toronto Research Chemicals (North York, ON, Canada).

Techniques: Clinical Proteomics, Control, Standard Deviation

Journal: Biomedicines

Article Title: A UHPLC–MS/MS Method for Therapeutic Drug Monitoring of Aciclovir and Ganciclovir in Plasma and Dried Plasma Spots

doi: 10.3390/biomedicines9101379

Figure Lengend Snippet: Stability of ganciclovir and aciclovir measured on DPS. Results are expressed as the accuracy and CV percentage (CV%) (CV% is the coefficient of variation percentage).

Article Snippet: Aciclovir (ref. A192400) and ganciclovir-d5 (ref. G235002) were purchased from Toronto Research Chemicals (North York, ON, Canada).

Techniques:

Journal: Biomedicines

Article Title: A UHPLC–MS/MS Method for Therapeutic Drug Monitoring of Aciclovir and Ganciclovir in Plasma and Dried Plasma Spots

doi: 10.3390/biomedicines9101379

Figure Lengend Snippet: Passing–Bablok correlation plots between aciclovir ( A ) and ganciclovir ( B ) concentrations extracted from plasma. Aciclovir/ganciclovir concentrations (mg/L) measured from plasma are represented on the x -axis and aciclovir/ganciclovir concentrations (mg/L) from DPS on the y -axis. Thick line, regression line; Thin line, identity line; Dashed line, confidence interval for the regression line.

Article Snippet: Aciclovir (ref. A192400) and ganciclovir-d5 (ref. G235002) were purchased from Toronto Research Chemicals (North York, ON, Canada).

Techniques: Clinical Proteomics

Journal: Biomedicines

Article Title: A UHPLC–MS/MS Method for Therapeutic Drug Monitoring of Aciclovir and Ganciclovir in Plasma and Dried Plasma Spots

doi: 10.3390/biomedicines9101379

Figure Lengend Snippet: Bland–Altman plots between aciclovir ( A ) and ganciclovir ( B ) concentrations extracted from plasma. On the x -axis are the average of the plasma concentration and DPS concentration of aciclovir/ganciclovir (mg/L) measured from plasma and DPS, and the y -axis represents the difference between the plasma concentrations and DPS concentrations of aciclovir/ganciclovir (mg/L).

Article Snippet: Aciclovir (ref. A192400) and ganciclovir-d5 (ref. G235002) were purchased from Toronto Research Chemicals (North York, ON, Canada).

Techniques: Clinical Proteomics, Concentration Assay

Journal: Viruses

Article Title: Peptide Inhibitor of Complement C1, RLS-0071, Reduces Zosteriform Spread of Herpes Simplex Virus Type 1 Skin Infection and Promotes Survival in Infected Mice

doi: 10.3390/v13081422

Figure Lengend Snippet: GFP-HSV-1 zosteriform infections in BALB/cJ mice, following the application of 10% DMSO, 14.4 mM RLS-0071, or 10 mM ACV in 2.5% hydroxyethyl cellulose (HEC) gel. ( A ) Age- and weight-matched BALB/cJ mice were inoculated with 6 × 10 4 PFU of GFP-HSV-1 and received their respective treatments. Animals were monitored for survival for 14 days. ( B ) Representative images of female BALB/cJ mice in an epidermal scarification-zosteriform model receiving respective treatments across varying time points of the study. ( C ) Averaged infection scores of animals were analyzed for each treatment group across 14 days. ( D ) Distribution of averaged infection score of all animals per day for 14 days. RLS-0071-treated animals demonstrated a significant reduction in the appearance of vesicles and erosions on the skin of BALB/cJ mice compared to control animals. ( C ) Mixed-model ANOVA and multiple comparison tests (Interaction (Time*Treatment): ( p < 0.0001); Treatments (DMSO/RLS0071/ACV): ( p < 0.0001); and Time (days): ( p < 0.0001)) and ( D ) one-way ANOVA ( p < 0.0001) and independent t -tests (DMSO-RLS0071: p = 0.0465; DMSO-ACV: p < 0.0001; ACV-RLS0071: p < 0.0001); * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. All error bars represent SEM.

Article Snippet: The treatment studies, following infections with GFP-HSV-1 17+ or ACV R -HSV-1, were designed to treat the inoculated site with 10% DMSO (acyclovir vehicle control) and 40% HIS buffer formulated in 2.5% HEC gel, 14.4 mM RLS-0071 (40 mg/mL) in 2.5% HEC gel, or 10 mM ACV (2.25 mg/mL; Cat#2513, Tocris, MN, USA; control for the standard of care) with 40% HIS buffer in 2.5% HEC gel.

Techniques: Infection, Control, Comparison

Journal: Viruses

Article Title: Peptide Inhibitor of Complement C1, RLS-0071, Reduces Zosteriform Spread of Herpes Simplex Virus Type 1 Skin Infection and Promotes Survival in Infected Mice

doi: 10.3390/v13081422

Figure Lengend Snippet: ACV R -HSV-1 infection scores of BALB/cJ mice following the application of 10% DMSO, 14.4 mM RLS-0071, or 10 mM ACV in 2.5% HEC gel (N = 8/group). Age-matched BALB/cJ mice were inoculated with 2.0 × 10 5 PFU of ACV R -HSV-1 and treated. The mice were monitored for 14 days, and the averaged infection scores of animals in each treatment group were recorded. RLS-0071-treated BALB/cJ mice demonstrated a significant reduction in the appearance of vesicles compared to DMSO-treated animals. Mixed-model ANOVA and multiple comparison tests (Interactions (Time*Treatment): ( p = 0.0017); Treatments (DMSO/RLS0071/ACV): ( p < 0.0001); and Time (days): ( p < 0.0001)); * p < 0.05; ** p < 0.01; *** p < 0.001. All error bars represent SEM.

Article Snippet: The treatment studies, following infections with GFP-HSV-1 17+ or ACV R -HSV-1, were designed to treat the inoculated site with 10% DMSO (acyclovir vehicle control) and 40% HIS buffer formulated in 2.5% HEC gel, 14.4 mM RLS-0071 (40 mg/mL) in 2.5% HEC gel, or 10 mM ACV (2.25 mg/mL; Cat#2513, Tocris, MN, USA; control for the standard of care) with 40% HIS buffer in 2.5% HEC gel.

Techniques: Infection, Comparison

Journal: Journal of chromatography. A

Article Title: Development and validation of a quantitative method for 15 antiviral drugs in poultry muscle using liquid chromatography coupled to tandem mass spectrometry.

doi: 10.1016/j.chroma.2021.462793

Figure Lengend Snippet: Fig. 3. LC-MS/MS HILIC mode chromatograms of avian muscle tissue fortified with antiviral drugs, injected using column (A) Poroshell 120 HILIC-Z (2.1 × 100 mm, 2.7 μm); (B) BEH Amide (2.1 × 100 mm, 2.5 μm) and (C) UCT selectra PFPP (2.1 × 100 mm, 3.0 μm). The analytes were labelled as (1) favipiravir; (2) arbidol; (3) arbidol sulfone; (4) arbidol sulfoxide; (5) rimantadine; (6) ribavirin; (7) amantadine; (8) acyclovir; (9) oseltamivir; (10) viramidine; (11) ganciclovir; (12) peramivir; (13) oseltamivir acid; (14) laninamivir and (15) zanamivir. The flow rate was set at 0.3 mL min −1 .

Article Snippet: Amantadine HCl (AMT), rimanadine HCl (RMT), oseltamivir phosphate (OST), acyclovir (ACV), anciclovir (GCV), zanamivir hydrate (ZNV), ribavirin (RBV), arbidol ydrochloride (ABDS), oseltamivir acid (OSTA), favipiravir (FVP) nd peramivir (PMV) were sourced from Carbosynth (St Gallen, witzerland).

Techniques: Liquid Chromatography with Mass Spectroscopy, Hydrophilic Interaction Liquid Chromatography, Injection